The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
Agurell S., Carlsson S., Lindgren J.E., Ohlsson A., Gillespie H., Hollister L.E. (1981) Interactions of Δ1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia37: 1090-1091
2.
Beneke M., Kuemmel B., Roed I.S., Spechtmeyer H. (1988) Treatment of anxiety neurosis with ipsapirone. Psychopharmacology96 (suppl): 353
3.
Biaggio A M B, Natalicio L., Spielberger C.D. (1976) The development and validation of an experimental portuguese form of the state-trait anxiety inventory. In Spielberger C D (ed.), Cross-cultural research on anxiety. Hemisphere/Wiley , Washington DC, p. 29
4.
Bond A., Lader M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol47: 211-218
5.
Carlini E.A., Santos M., Claussen V., Bieniek D., Korte F. (1970) Structure activity relationship of four tetrahydrocannabinol and the pharmacological activity of five semipurified extracts of Cannabis sativa. Psychopharmacology18: 82-93
6.
Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., Kennedy K., Schram K. (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav40: 701-708
7.
Critchley Mae, Handley S.L. (1987) 5-HT1a ligand effects in the X-maze anxiety test . Br J Pharmacol92: 660 P
8.
Csanalosi I., Schweizer E., Case W.G., Rickels K. (1987) Gepirone in anxiety: a pilot study. J Clin Psychopharmacol7: 31
9.
Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology21: 175-185
10.
Dalton W.S., Martz R., Lemberger L., Rodda B.E., Forney R.B. (1976) Influence of cannabidiol on Δ9-tetrahydrocannabinol effects. Clin Pharmacol Ther19: 300-309
11.
De Vry J., Glaser T., Schuman T., Schreiber R., Traber J. (1991) 5-HT1a receptors in anxiety. In Briley M, File S E (eds), New concepts in anxiety. MacMillan Press, London, pp. 94-129
12.
Deakin J F W, Guimarães F.S., Wang M., Hellewell J., HensmanR (1991) 5-HT receptor mechanisms in human anxiety. In Briley M, File S E (eds), New concepts in anxiety. MacMillan Press, London, pp. 74-93
13.
Deakin J F W, Graeff F.G., Guimarães F.S. (1992) 5-HT receptor subtypes and the modulation of aversion . In Marsden C A, Heal D J (eds), Central serotonin receptors and psychotropic drugs. Blackwell Scientific Publication, Oxford, pp. 147-174
14.
Eison A., Yocca F.D. (1985) Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol11: 389-392
15.
Geer J.H. (1965) The development of a scale to measure fear. Behav Res Ther193: 785-795
16.
Goa K., Ward A. ( 1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs32: 114-129
17.
Graeff F.G., Zuardi A.W., Giglio J.S., Lima Filho E.C., Karniol I.G. (1985) Effect of metergoline on human anxiety. Psychopharmacology86: 334-338
18.
Gregg J.M., Small E.W., Moore R., Raft D., Toomey T.C. (1976) Emotional response to intravenous Δ9-tetrahydrocannabinol during oral surgery. J Oral Surg34: 301-313
19.
Guimarães F.S., Zuardi A.W., Graeff F.G. (1987) Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J Psychopharmacology1: 184-192
20.
Guimarães F.S., Kohem C.L., Gus G., Fillman H.S., De Vecino M C A, De Paoli C.L., Ribeiro A M S, Teixeira C.C., Wannmacher L. (1989) A simple simulated public speaking test for evaluating anxiolytic drugs. Brazilian J Med Biol Res22: 1083-1089
21.
Guimarães F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology100: 558-559
22.
Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA87: 1931-1936
23.
Higgins G.A., Jones B.J., Oakley N.R. (1987) Compounds selective for the 5HT1a receptors have anxiolytic effects when injected into the dorsal raphe nucleus of the rat . Br J Pharmacol92: 658P
24.
Karniol I.G., Carlini E.A. (1973) Pharmacological interaction between cannabidiol and Δ9-tetrahydrocannabinol. Psychopharmacology33: 53-70
25.
Karniol I.G., Shirakawa I., Kasiski N., Pfeferman A., Carlini E.A. (1974) Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol28: 172-177
26.
Kostowski W., Plaznik A., Stefanski R. (1989) Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol168: 393-396
27.
Kuemmel B., Beneke M., Krol G., Schoellnhammer G., Spechtmeyer H. (1988) Ipsapirone in the treatment of generalized anxiety disorders. Results of a phase II US-multicenter trial. Psychopharmacology96 (suppl): 353
28.
Lovik T.A. (1990) Selective modulation of the cardiovascular response but not the antinociception evoked from the dorsal PAG, by 5-HT in the ventrolateral medulla. Pflügers Arch416: 222-224
29.
Malit L.A., Johnstone R.F., Bourke D.I., Kulp R.A., Klein D., Eng D., Smith T.C. (1975) Intravenous Δ9-tetrahydrocannabinol effects on ventilatory and cardiovascular dynamics. Anesthesiology42: 666-673
30.
Marsden C.A. (1989) 5-hydroxytryptamine receptor subtypes and new anxiolytic drugs: an appraisal. In Tyrer P (ed.), Psychopharmacology of anxiety. Oxford University Press, Oxford, pp. 3-27
31.
Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. (1990) Structure of a cannabinoid receptor and functional expression of cloned cDNA. Nature346: 561-564
32.
McNair D.M., Frankenthaler I.M., Czerlinsky T., White T.W., Sasson S., Fisher S. (1982) Simulated public speaking as a model of clinical anxiety. Psychopharmacology77: 7-10
33.
Norris H. (1971) The action of sedatives on brainstem oculomotor systems in man. Neuropharmacology10: 181-191
34.
Norusis M.J. (1988) SPSS/PC+ advanced stataistics V. 2.0SPSS Inc., Chicago
35.
Nye J.S., Seltzman H.H., Pitt C.G., Snyder S.H. (1985) High-affinity cannabinoid binding sites in brain membranes labelled with 3H-5'-trimethylammonium Δ8-tetrahydrocannabinol . J Pharmacol Exp Ther234: 784-791
36.
Onaivi E.S., Green M.R., Martin B.R. (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther253: 1002-1009
37.
Saxena P.R., Villalón C.M. (1990) Brain 5-HT1a receptor agonism: a novel mechanism for antihypertensive action. Trends Pharmacol Sci11: 95-96
38.
Spielberger C.D., Gorsuch R.L., Lushene R.E. (1970) Manual for the state-trait anxiety inventory. Consulting Psychologist Press, Paolo Alto .
39.
Tassinari C.A., Ambrosetto G., Peraita-Adrados MR, Gestaut H. (1976) The neuropsychiatric syndrome of Δ9-tetrahydrocannabinol and cannabis intoxication in naive subjects: a clinical and polygraphic study during wakefulness and sleep. In Braude M C, Szara S (eds), The pharmacology of marihuana. Raven Press, New York, pp.357-375
40.
Teicher M.H. (1988) Biology of anxiety. Med Clin North Am72: 791-814
41.
Wechsler D. (1955) Manual for the Wechsler adult intelligence scale . The Psychological Corporation, New York
42.
Zuardi A.W., Karniol I.G. (1981) Transcultural evaluation of a self-evaluation scale of subjective states. J Brasileiro Psiquiatr131: 403-406
43.
Zuardi A.W., Karniol I.G. (1983) Changes in the conditioned emotional response of rats induced by Δ9-tetrahydrocannabinol, CBD and mixture of the two cannabinoids . Ar Biol Technol26: 391-397
44.
Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. (1982) Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology76: 245-250
